Close

AstraZeneca (AZN) Offers pre-Specificed Subgroup Analysis of FALCON Trial; PFS Seen as Largely Consistent

December 8, 2016 8:32 AM EST Send to a Friend
AstraZeneca (NYSE: AZN) announced results from a pre-specified subgroup analysis of the positive Phase III FALCON trial suggesting that treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login